Claritas Pharmaceuticals, Inc. Stock

CLAZF

CA1806342061

Biotechnology & Medical Research

Market Closed - OTC Markets 12:16:04 2026-02-27 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap	5.37M 3.9M 3.34M 3.12M 2.86M 373M 5.44M 36.92M 14.4M 187M 14.64M 14.32M 620M	P/E 2019	-0.74x	P/E 2020	0.13x
Enterprise Value	6.29M 4.57M 3.91M 3.66M 3.35M 437M 6.37M 43.25M 16.87M 220M 17.15M 16.78M 726M	EV / Sales 2019	-	EV / Sales 2020	-
Free-Float	99.74%	Yield 2019 *	-	Yield 2020	-

* Estimated data More valuation ratios

Chart: Claritas Pharmaceuticals, Inc.

Dynamic Chart

Managers and Directors: Claritas Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Farrell CEO	Chief Executive Officer	76	2017-06-20
Victoria Rudman DFI	Director of Finance/CFO	58	2018-06-28

Director	Title	Age	Since
Robert Farrell CHM	Chairman	76	2021-03-17

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CLARITAS PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	37
LONZA GROUP AG	+1.09%	+5.26%	+4.44%	+26.03%	51.61B
REVOLUTION MEDICINES, INC.	-1.07%	+2.82%	+474.18%	+601.24%	44.89B
IQVIA HOLDINGS INC.	+1.47%	+9.79%	+40.15%	+21.21%	42.77B
BEONE MEDICINES AG	+1.44%	+7.77%	+19.27%	+90.94%	42.58B
CELLTRION, INC.	-0.93%	-4.33%	+17.87%	+51.96%	31.82B
MEDPACE HOLDINGS, INC.	+1.32%	+7.30%	+36.93%	+152.36%	17.33B
ASCENDIS PHARMA A/S	-0.60%	+1.93%	-	-	16.63B
EUROFINS SCIENTIFIC SE	+0.03%	+3.41%	+7.12%	+35.49%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	+5.41%	+91.01%	+46.93%	14.09B
Average	+0.40%	+3.99%	+86.37%	+128.27%	27.65B
Weighted average by Cap.	+0.49%	+4.72%	+102.57%	+148.52%

See all sector performances

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâ€™s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
CLAZF Stock

The best tools reserved for subscribers to boost the performance of your investments!

Maximize my profits

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.4
10 years	0		15.31

Date	Insider	Type	Quantity	% Market Cap.
10/11/21	Andrew Salzman	Buy	118,000	0.3332%
10/11/21	Andrew Salzman	Buy	152,500	0.4307%
10/11/21	Andrew Salzman	Buy	24,500	0.0692%

	2019	2020
Net sales	-	-
Net income	-21.21M -15.41M -13.2M -12.35M -11.3M -1.47B -21.49M -146M -56.89M -740M -57.85M -56.59M -2.45B	4.21M 3.06M 2.62M 2.45M 2.24M 293M 4.27M 28.95M 11.29M 147M 11.48M 11.23M 486M
Net Debt	704K 511K 438K 410K 375K 48.92M 713K 4.84M 1.89M 24.57M 1.92M 1.88M 81.28M	920K 668K 572K 536K 490K 63.93M 932K 6.33M 2.47M 32.11M 2.51M 2.45M 106M

Claritas Pharmaceuticals, Inc. Stock

Stocks

CLAZF

CA1806342061

Biotechnology & Medical Research

Valuation: Claritas Pharmaceuticals, Inc.

Chart: Claritas Pharmaceuticals, Inc.

Course Extremes

Managers and Directors: Claritas Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile